Stock Market News1 month KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707 Zacks
Krystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy candidate, KB707.
XKrystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy candidate, KB707.
X